SCHEMBL8370360

SCHEMBL8370360

CCc1cc(-c2ccc(F)cc2)ccc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 3/20 0.64
MAPT P10636 2/20 0.49
HTT P42858 2/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
ALOX15 P16050 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ESR1 P03372 6/20 0.48
ESR2 Q92731 6/20 0.48
AR P10275 1/20 0.45
MEN1 O00255 1/20 0.45
PKM P14618 1/20 0.45
KMT2A Q03164 1/20 0.45
BACE1 P56817 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB2 P47870 1/20 0.44
CYP1A2 P05177 1/20 0.44
ERCC1 P07992 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13678958 0.90 HSD17B1 (0.75) HSD17B1ESR1ESR2ARBACE1
SCHEMBL3953461 0.88 HSD17B1 (0.71) HSD17B1ESR1ESR2ARBACE1
SCHEMBL5208612 0.85 ALOX5 (0.57) HSD17B1MAPTHTTLMNAESR1
SCHEMBL2720462 0.84 HSD17B1 (0.68) HSD17B1ESR1ESR2ARMEN1
SCHEMBL26134242 0.84 HSD17B1 (0.68) HSD17B1ESR1ESR2ARMEN1
SCHEMBL364672 0.84 ESR1 (0.53) HSD17B1MAPTHTTKDM4ELMNA
SCHEMBL1023129 0.82 HSD17B1 (0.66) HSD17B1MAPTHTTKDM4ELMNA
SCHEMBL13652987 0.82 TTR (0.60) HSD17B1MAPTHTTKDM4ELMNA
SCHEMBL11023467 0.80 MMP1 (0.49) HSD17B1MAPTHTTKDM4ELMNA
SCHEMBL16581416 0.80 HSD17B1 (0.62) HSD17B1ESR1ESR2ARMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120301426-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-11-29 US disclosed
US-8258316-B2 Alkanoylamino benzamide aniline HDAC inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-09-04 US disclosed
US-20100310500-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310500-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS HDAC1, HDAC5, HDAC7 HSD17B1 497/4885MAPT 2031/4885HTT 541/4885
US-20120301426-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS HDAC1, HDAC5, HDAC7 HSD17B1 497/4885MAPT 2031/4885HTT 541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.